Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that v::RET status confers therapeutic sensitivity to Selpercatinib in patients with Non-Small Cell Lung Cancer.

The European Medicines Agency (EMA) has conditionally authorized selpercatinib for the treatment of adult patients with advanced RET fusion-positive non-small cell lung cancer not previously treated with a RET inhibitor.

This statement is based on a regulatory approval from the European Medicines Agency:

Retsevmo as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor.

Citation

Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2022-06-21	European Medicines Agency	Indication received approval from the European Commission.